Done sou Salè H1B

Akèy › Anplwayè › Janssen Global Services, LLC

Janssen Global Services, LLC: Salè H-1B ak pajon

Janssen Global Services, LLC depoze 16 aplikasyon kondisyon travay pou visa H-1B ak visa ki gen rapò nan ane fiskal 2023–2026; sètifye: 16. Medyèn salè yo ofri a: $242,200.

Demann (LCA)16
Certifye16
Adrès anplwayèNew Brunswick, NJ
Anplwayè H-1B depannNon
Salè medyan ofri$242,200
Mwatye salè yo$190,000–$305,475
10yèm–90yèm pousantaj$177,350–$347,000

Èske Janssen Global Services, LLC pajone visa H-1B?

Janssen Global Services, LLC depoze 16 aplikasyon kondisyon travay nan ane fiskal 2023–2026, dènye a soumèt sou Jun 16, 2026. Yon LCA se premye etap yon demann H-1B, konsa anplwayè a pajone oswa prepare pou pajone travayè H-1B; li pa garanti pajon pou okenn travay espesifik. Tcheke lis travay pwòp anplwayè a.

Salè pa tit travay

Tit travayLCASalè medyan
Senior Director Transactions Immunology, Acquisitions2$312,600
Associate Director, Global Market Access Oncology1$197,400
Associate Director, Health Economics Modeling1$190,000
Director, Global Commercial Strategy1$248,900
Senior Director, Transactions Immunology and Acquisitions1$312,300
Director Global Comm Strat Precision Medicine1$174,699
Associate Director, Global Real World Evidence (RWE)1$190,000
Head of Market Access, Oncology1$372,000
Director, Alliance Management1$235,500
Manager, Global RWE - Immunology1$180,000
Manager, Global RWE - Oncology1$170,000
Director, Global Medical Affairs Lead1$250,000
Senior Principal Data Scientist Global Data Science1$211,100
Medical Director Oncology Hematology1$266,200
VP, Therapeutic Area Market Access Leader, Oncology1$390,700

Aplikasyon pa ane fiskal

Ane fiskalLCASalè medyan
FY20245$248,900
FY20254$212,750
FY20267$250,000

Nivo salè prevanlan

Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.

Kote travay yo ye

Okipasyon

Dènye aplikasyon yo

Tit travaySalè bazKoteSoumètDat kòmansmanEstati
VP, Therapeutic Area Market Access Leader, Oncology$390,700
E-3 · Nivo IV
Raritan, NJJun 16, 2026Aug 20, 2026Certifye
Medical Director Oncology Hematology$266,200
Nivo IV
Raritan, NJJun 5, 2026Oct 1, 2026Certifye
Senior Principal Data Scientist Global Data Science$211,100
Nivo IV
Raritan, NJMay 28, 2026Oct 1, 2026Certifye
Director, Global Medical Affairs Lead$250,000
Nivo IV
Raritan, NJMay 5, 2026Oct 1, 2026Certifye
Senior Director Transactions Immunology, Acquisitions$322,000
E-3 · Nivo IV
New Brunswick, NJDec 26, 2025Jun 7, 2026Certifye
Manager, Global RWE - Oncology$170,000
Nivo III
Raritan, NJNov 5, 2025Nov 25, 2025Certifye
Manager, Global RWE - Immunology$180,000
Nivo III
Raritan, NJNov 5, 2025Nov 17, 2025Certifye
Director, Alliance Management$235,500
Nivo IV
Titusville, NJSep 15, 2025Nov 1, 2025Certifye
Director Global Comm Strat Precision Medicine$174,699–$285,000
Nivo IV
Raritan, NJDec 20, 2024May 2, 2025Certifye
Associate Director, Global Real World Evidence (RWE)$190,000
Nivo III
Raritan, NJDec 5, 2024Dec 16, 2024Certifye
Head of Market Access, Oncology$372,000
E-3 · Nivo IV
Raritan, NJSep 30, 2024Oct 15, 2024Certifye
Senior Director, Transactions Immunology and Acquisitions$312,300
E-3 · Nivo IV
New Brunswick, NJApr 5, 2024Jul 8, 2024Certifye
Director, Global Commercial Strategy$248,900
E-3 · Nivo III
Raritan, NJFeb 5, 2024Apr 10, 2024Certifye
Senior Director Transactions Immunology, Acquisitions$303,200
E-3 · Nivo IV
New Brunswick, NJJan 5, 2024May 20, 2024Certifye
Associate Director, Global Market Access Oncology$197,400
Nivo IV
Raritan, NJDec 4, 2023May 25, 2024Certifye
Associate Director, Health Economics Modeling$190,000
Nivo III
Raritan, NJNov 28, 2023Dec 11, 2023Certifye

Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).